Award Notice
Bupropion HCL ER
Dept of Defense · Defense Logistics Agency · Sol. SPE2D2-23-D-0002
No deadlineClosed
This contract has been awarded
Awarded to Radha Pharmaceuticals Inc for $23.3M on Oct 6, 2022.
Recent DLA contract awards: who won →
These similar contracts are still open:
- Febuxostat TabletsDLA Troop Support wants one national supplier of febuxostat tablets (40 mg and 80 mg, 30-count bottles) for the DoD and VA pharmacy prime vendor programs.
- Latanoprost Ophthalmic Solution (VA-27-00006027)The VA Enterprise Procurement Office plans to buy Latanoprost eye drops (an ophthalmic solution) for VA, DoD, Bureau of Prisons, Indian Health Service and the Federal Health Care…
- Imatinib TabletsThe Department of Veterans Affairs (National Acquisition Center) plans to award one contract for imatinib mesylate tablets, a cancer drug, to supply VA, DoD, Bureau of Prisons,…
- Methylphenidate ERThe Defense Logistics Agency (DLA Troop Support) plans a national requirements contract for Methylphenidate ER tablets (18, 27, 36 and 54 mg, 100-count bottles).
- Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount ProgramThe Defense Health Agency is asking drug manufacturers to quote discounted prices and refunds on 12 newly FDA-approved brand drugs so its Pharmacy and Therapeutics Committee can…
AI summary Beta
No AI summary for this notice yet.
Save it to generate your own AI brief in its bid workspace: a plain-English summary, the red flags, and how well your business fits.
Key facts
- Posted
- Sep 14, 2026
- Notice type
- Award Notice
- Solicitation
- SPE2D2-23-D-0002
- Agency
- Dept of Defense · Defense Logistics Agency
- Office
- DLA Troop Support
- NAICS
- 325412
- Product/service code
- 6505
- Business type
- Medical & healthcare
- Place of performance
- Hauppauge, NY, 11788
- Contracting contact
- Kyle Lewickikyle.lewicki@dla.mil4457370977
Before you respond
Full notice text from SAM.gov
Modification P00010 SPE2D223D0002 is issued to invoke option year 4 for Bupropion HCL ER National Contract. Modification P00009 SPE2D223D0002 is issued to incorporate clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1) (APR 2026). Modification P00008 SPE2D223D0002 is issued to invoke option year 3 for Bupropion HCL ER National Contract. Modification P00007 SPE2D223D0002 is issued in accordance with DoD Class Deviation 2025-O0003 and Class Deviation 2025-O0004 into subject solicitation. Modification P00006 SPE2D223D0002 is issued to invoke option year 2 for Bupropion HCL ER National Contract. Modification P00005 SPE2D223D0002 is issued to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders into subject solicitation. NATIONAL CONTRACT SPE2D2-23-D-0002 BUPROPION HCL ER